COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022
- PMID: 35324880
- PMCID: PMC8956338
- DOI: 10.15585/mmwr.mm7112e2
COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022
Abstract
Beginning the week of December 19-25, 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2 (the virus that causes COVID-19) became the predominant circulating variant in the United States (i.e., accounted for >50% of sequenced isolates).* Information on the impact that booster or additional doses of COVID-19 vaccines have on preventing hospitalizations during Omicron predominance is limited. Data from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET)† were analyzed to compare COVID-19-associated hospitalization rates among adults aged ≥18 years during B.1.617.2 (Delta; July 1-December 18, 2021) and Omicron (December 19, 2021-January 31, 2022) variant predominance, overall and by race/ethnicity and vaccination status. During the Omicron-predominant period, weekly COVID-19-associated hospitalization rates (hospitalizations per 100,000 adults) peaked at 38.4, compared with 15.5 during Delta predominance. Hospitalizations rates increased among all adults irrespective of vaccination status (unvaccinated, primary series only, or primary series plus a booster or additional dose). Hospitalization rates during peak Omicron circulation (January 2022) among unvaccinated adults remained 12 times the rates among vaccinated adults who received booster or additional doses and four times the rates among adults who received a primary series, but no booster or additional dose. The rate among adults who received a primary series, but no booster or additional dose, was three times the rate among adults who received a booster or additional dose. During the Omicron-predominant period, peak hospitalization rates among non-Hispanic Black (Black) adults were nearly four times the rate of non-Hispanic White (White) adults and was the highest rate observed among any racial and ethnic group during the pandemic. Compared with the Delta-predominant period, the proportion of unvaccinated hospitalized Black adults increased during the Omicron-predominant period. All adults should stay up to date (1) with COVID-19 vaccination to reduce their risk for COVID-19-associated hospitalization. Implementing strategies that result in the equitable receipt of COVID-19 vaccinations, through building vaccine confidence, raising awareness of the benefits of vaccination, and removing barriers to vaccination access among persons with disproportionately higher hospitalizations rates from COVID-19, including Black adults, is an urgent public health priority.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Evan J. Anderson reports grants from Pfizer, Merck, PaxVax, Micron, Sanofi-Pasteur, Janssen, MedImmune, and GlaxoSmithKline; personal fees from Pfizer, Medscape, Kentucky Bioprocessing, Inc., Sanofi-Pasteur, and Janssen, outside the submitted work; and institutional funding from the National Institutes of Health to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. Laurie M. Billing and Kenzie Teno report grants from the Council of State and Territorial Epidemiologists during the conduct of the study. Libby Reeg reports grants from the Michigan Department of Health and Human Services during the conduct of the study. No other potential conflicts of interest were disclosed.
Figures


Similar articles
-
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35085224 Free PMC article.
-
Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022.MMWR Morb Mortal Wkly Rep. 2022 Aug 26;71(34):1085-1091. doi: 10.15585/mmwr.mm7134a3. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36006841 Free PMC article.
-
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35176007 Free PMC article.
-
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.Front Public Health. 2022 Jul 13;10:940956. doi: 10.3389/fpubh.2022.940956. eCollection 2022. Front Public Health. 2022. PMID: 35910897 Free PMC article.
-
Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.BMC Infect Dis. 2023 Jun 26;23(1):432. doi: 10.1186/s12879-023-08328-3. BMC Infect Dis. 2023. PMID: 37365490 Free PMC article.
Cited by
-
Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece.J Clin Med. 2022 Dec 2;11(23):7172. doi: 10.3390/jcm11237172. J Clin Med. 2022. PMID: 36498745 Free PMC article.
-
Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study.Lancet Reg Health Am. 2023 Jul;23:100530. doi: 10.1016/j.lana.2023.100530. Epub 2023 Jun 14. Lancet Reg Health Am. 2023. PMID: 37333688 Free PMC article.
-
Health equity in COVID-19 testing among patients of a large national pharmacy chain.Front Public Health. 2024 Sep 11;12:1422914. doi: 10.3389/fpubh.2024.1422914. eCollection 2024. Front Public Health. 2024. PMID: 39324167 Free PMC article.
-
Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review.Vaccines (Basel). 2023 Sep 19;11(9):1502. doi: 10.3390/vaccines11091502. Vaccines (Basel). 2023. PMID: 37766178 Free PMC article. Review.
-
Trends in Severe Outcomes Among Adult and Pediatric Patients Hospitalized With COVID-19 in the Canadian Nosocomial Infection Surveillance Program, March 2020 to May 2022.JAMA Netw Open. 2023 Apr 3;6(4):e239050. doi: 10.1001/jamanetworkopen.2023.9050. JAMA Netw Open. 2023. PMID: 37079304 Free PMC article.
References
-
- CDC. Stay up to date with your COVID-19 vaccines. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Accessed March 10, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html
-
- Delahoy MJ, Whitaker M, O’Halloran A, et al.; COVID-NET Surveillance Team. Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19—COVID-NET, 13 states, March 1–August 22, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1347–54. 10.15585/mmwr.mm6938e1 - DOI - PMC - PubMed
-
- Johnson AG, Amin AB, Ali AR, et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence—25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–8. 10.15585/mmwr.mm7104e2 - DOI - PMC - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous